stockrow
Friday 6 November 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
30.53
2.14
+7.54%
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) EBITDA
Immunovant, Inc.'s EBITDA for fiscal 2026 was −$532.5M, compared with −$437.8M in fiscal 2025. Over the twelve months to 30 June 2026 it was −$565.6M. Over the past ten years it has ranged from −$532.5M (fiscal 2026) to −$500.00 (fiscal 2018) — the current reading is the lowest in ten years. EBITDA has fallen for 8 consecutive fiscal years. Immunovant, Inc. ranks 583rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | −$532.5M | — |
| FY2025 | −$437.8M | — |
| FY2024 | −$282.5M | — |
| FY2023 | −$218.1M | — |
| FY2022 | −$155.9M | — |
| FY2021 | −$108.1M | — |
| FY2020 | −$66.1M | — |
| FY2019 | −$28.4M | — |
| FY2018 | −$500.00 | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$160.2M | — |
| Mar 2026 | −$159.5M | — |
| Dec 2025 | −$114.3M | — |
| Sep 2025 | −$131.7M | — |
| 26 more quarters | Free account |
Against its own ten years
Low −$532.5M
High −$500.00
Ten-year median
−$155.9M
Current reading's percentile
11
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| LGND Ligand Pharmaceuticals Incorporated compare | $57.3M |
| MANE Veradermics Incorporated compare | −$88.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| IMVT Immunovant, Inc. | −$565.6M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item